ProCE Banner Activity

Latest Research and Clinical Development With Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Clinical Thought

Exciting new research and clinical developments for the use of novel bispecific antibodies and combinations may continue to refine treatment options for the management of patients with relapsed/refractory multiple myeloma.

Released: May 20, 2025

Expiration: May 19, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC.

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by a grant from Pfizer Inc. Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pfizer, Inc.

Regeneron Pharmaceuticals, Inc

Faculty Disclosure

Primary Author

Noopur Raje, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Caribou, Genentech, Immuneel, Johnson & Johnson, Pfizer, Sanofi.